Ellie Leick

Articles

Standard Myeloma Therapies Transform to Triplet, Quadruplet Regimens

February 25th 2020

Caitlin Costello, MD, discusses pivotal research in the relapsed/refractory multiple myeloma setting.

Novel Approaches Under Exploration Across Lymphoma Subtypes

February 24th 2020

Erin Reid, MD, discusses the treatment advances across lymphomas and the remaining questions that need to be answered with further research.

Pal Highlights Encouraging ORR With Cabozantinib Plus Atezolizumab in mCRPC

February 24th 2020

Sumanta K. Pal, MD, discusses the cohort 6 findings of the COSMIC-021 trial and other key data that were presented during the 2020 Genitourinary Cancers Symposium.

Musculoskeletal Tumor Registry Collects QoL Data After Surgery in Sarcoma

February 21st 2020

Benjamin J. Miller, MD, MS, discusses the creation of the Musculoskeletal Tumor Registry and how it is poised to make progress in the orthopedic oncology field.

HER2+ Breast Cancer Treatment Arsenal Expands With ADCs

February 20th 2020

Sara A. Hurvitz, MD, Neelima Denduluri, MD, and Madelaine Kuiper, MSN, RN, discuss the rise of HER2-targeted therapies and their implications on the field.

O'Regan Shares Insight on Biosimilar Revolution in Oncology

February 19th 2020

Ruth O’Regan, MD, shares her perspective on the use of biosimilars in breast cancer and their future in oncology.

Newer ALK+ NSCLC Options Focus on Targeting Acquired Resistance

February 19th 2020

Anne Chiang, MD, PhD, discusses the currently available treatments and ongoing research in ALK-positive non–small cell lung cancer.

Somatic Testing Could Be Standard Approach in Endometrial Cancer

February 18th 2020

Julia Fehniger, MD, discusses emerging strategies in the treatment paradigm for patients with BRCA1/2-mutant endometrial cancer.

Retrospective Results Show High pCR With Dose-Dense Regimen in HER2+ Breast Cancer

February 15th 2020

Jasmeet C. Singh, MD, discusses the findings of a retrospective analysis and how they may impact treatment for patients with HER2-positive breast cancer.

Brahmer Highlights Next Steps for Osimertinib in EGFR-Mutant NSCLC

February 10th 2020

Julie R. Brahmer, MD, discusses the impact of osimertinib in EGFR-mutant non–small cell lung cancer, ongoing research with the agent, and the importance of molecular testing.

Novel Agents Move Through Relapsed/Refractory Myeloma Pipeline

February 10th 2020

Shebli Atrash, MD, discusses some of the latest intriguing research in relapsed/refractory multiple myeloma.

Therapeutic Advances Promote Personalized Medicine in Advanced NSCLC

February 10th 2020

Significant research advances in targeted therapy and immunotherapy within the past years have created a more personalized approach to treatment for patients with advanced non–small cell lung cancer.

Emerging Targeted Therapies Emphasize Need for Molecular Testing in Lung Cancer

February 8th 2020

Benjamin P. Levy, MD, discusses emerging oncogenic markers in lung cancer and what impact they are poised to make on the paradigm.

Biosimilars Enter US Market, Poised to Impact Cancer Treatment

February 5th 2020

Adam M. Brufsky, MD, PhD, FACP, discusses the emergence of biosimilars in oncology and how he anticipates they will change the paradigm.

Immunotherapy Research Continues to Improve Patient Selection in NSCLC

February 5th 2020

Roy S. Herbst, MD, PhD, discusses research regarding immunotherapy and accompanying biomarkers in non–small cell lung cancer.

CDK4/6 Inhibitors Alter HR+ Breast Cancer Paradigm

February 4th 2020

Melissa K. Accordino, MD, MS, discusses the treatment options for patients with hormone receptor-positive, HER2-negative breast cancer.

Potential Immunotherapy Response Markers Emerge in Metastatic Breast Cancer

February 4th 2020

James M. Reuben, PhD, MBA, discusses his research on using liquid biopsies to identify predictive biomarkers for immunotherapy in patients with metastatic breast cancer.

Novel Surgical Technique Alleviates Adverse Events After Amputation in Patients With Cancer

January 30th 2020

Thomas J. Scharschmidt, MD, MBOE, discusses the use of targeted muscle reinnervation for amputee patients with cancer as well as therapeutic advances in sarcoma and tenosynovial giant cell tumor.

P16, P21 Biomarkers Linked to Treatment Response in Osteosarcoma

January 29th 2020

C. Parker Gibbs, MD, discusses the research behind p16 and p21 as predictive biomarkers for treatment response in patients with osteosarcoma.

Radiopharmaceuticals Show Signs of Progress in Prostate Cancer

January 29th 2020

A. Oliver Sartor, MD, discusses the development of radiopharmaceuticals in prostate cancer.